UGT1A6

UDP-glucuronosyltransferase 1A6 · P19224 · UGT1A6 on Sugi Atlas →

1,945 patent compounds predicted against UGT1A6, 1,606 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Diclofenac (SCHEMBL2799)	1.00	1/20
Diclofenac (SCHEMBL996716)	1.00	1/20
Diclofenac (SCHEMBL24010)	0.97	1/20
Diclofenac (SCHEMBL40785)	0.97	1/20
Diclofenac (SCHEMBL418230)	0.97	1/20
Diclofenac (SCHEMBL1178502)	0.97	1/20
Diclofenac (SCHEMBL1231246)	0.97	1/20
Diclofenac (SCHEMBL1651599)	0.97	1/20
Diclofenac (SCHEMBL2216520)	0.97	1/20
Diclofenac (SCHEMBL3176618)	0.97	1/20
Diclofenac (SCHEMBL3184302)	0.97	1/20
Diclofenac (SCHEMBL3466580)	0.97	1/20
Diclofenac (SCHEMBL4614418)	0.97	1/20
Diclofenac (SCHEMBL4615491)	0.97	1/20
Diclofenac (SCHEMBL6509236)	0.94	1/20
Diclofenac (SCHEMBL6765357)	0.91	1/20
Diclofenac (SCHEMBL4566078)	0.89	1/20
Diclofenac (SCHEMBL7776173)	0.89	1/20
Diclofenac (SCHEMBL2899504)	0.86	1/20
Diclofenac (SCHEMBL691812)	0.84	1/20

Clinical trials — most relevant to UGT1A6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial	PHASE3	UNKNOWN
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer	PHASE2	COMPLETED
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer	PHASE2	COMPLETED
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer	PHASE2	COMPLETED
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours	PHASE1	UNKNOWN
Cotinine Metabolism in Infants and Children	PHASE1	COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin	PHASE1	COMPLETED
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease	PHASE1	COMPLETED
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors	PHASE1	UNKNOWN
Irinotecan in Treating Asian Patients With Solid Tumors	PHASE1	COMPLETED
OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Study of NK012 in Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma	PHASE1	COMPLETED
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors	PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI	nan	COMPLETED
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy	nan	RECRUITING
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype	nan	UNKNOWN
Escalated Dose of Irinotecan in mCRC	nan	COMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C	nan	COMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants	nan	COMPLETED
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a UGT1A6 binder may also engage these)

Protein	Name	Similarity
P08430	—	1.000	P08430 →
Q64435	—	1.000	Q64435 →
UGT1A4	UDP-glucuronosyltransferase 1A4	1.000	landscape →
Q28612	—	0.996	Q28612 →
Q64550	—	0.995	Q64550 →
Q64638	—	0.992	Q64638 →
P70691	—	0.992	P70691 →
UGT1A3	UDP-glucuronosyltransferase 1A3	0.990	landscape →
Q64637	—	0.990	Q64637 →
P35504	—	0.989	P35504 →
P20720	—	0.989	P20720 →
Q63886	—	0.989	Q63886 →
UGT1A1	UDP-glucuronosyltransferase 1A1	0.988	landscape →
Q28611	—	0.986	Q28611 →
Q6ZQM8	—	0.983	Q6ZQM8 →
Q64634	—	0.981	Q64634 →
Q80X89	—	0.980	Q80X89 →
Q6PDD0	—	0.976	Q6PDD0 →
P36512	—	0.974	P36512 →
Q62452	—	0.974	Q62452 →
UGT2B17	UDP-glucuronosyltransferase 2B17	0.974	landscape →
O02663	—	0.974	O02663 →
O77649	—	0.972	O77649 →
Q64633	—	0.970	Q64633 →
P36510	—	0.970	P36510 →
O19103	—	0.969	O19103 →
P54855	—	0.968	P54855 →
P19488	—	0.968	P19488 →
P0DTE5	—	0.968	P0DTE5 →
Q9TSL6	—	0.967	Q9TSL6 →